tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Microbot Medical Showcases Robotics at Strasbourg Event

Story Highlights
  • Microbot Medical is participating in the inaugural Endovascular Robotics session at the Society of Robotic Surgery annual meeting.
  • The company is preparing for the U.S. launch of its LIBERTY system, pending FDA 510(k) clearance.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Microbot Medical Showcases Robotics at Strasbourg Event

Elevate Your Investing Strategy:

The latest announcement is out from Microbot Medical ( (MBOT) ).

On July 8, 2025, Microbot Medical announced its participation in the inaugural Endovascular Robotics session at the Society of Robotic Surgery annual meeting in Strasbourg, France, from July 16-20. This event highlights the growing importance of robotics in endovascular procedures, with Microbot Medical using the platform to showcase its LIBERTY Endovascular Robotic System. The company is also preparing for the U.S. launch of LIBERTY, pending FDA 510(k) clearance, and is enhancing its sales and marketing efforts in anticipation of this decision.

The most recent analyst rating on (MBOT) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.

More about Microbot Medical

Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics. The company has developed the world’s first single-use, fully disposable endovascular robotic system, aiming to improve the quality of care for patients and providers globally.

Average Trading Volume: 2,690,878

Technical Sentiment Signal: Buy

Current Market Cap: $91.31M

For a thorough assessment of MBOT stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1